BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35181585)

  • 1. HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation.
    Hrbac T; Kopkova A; Siegl F; Vecera M; Ruckova M; Kazda T; Jancalek R; Hendrych M; Hermanova M; Vybihal V; Fadrus P; Smrcka M; Sokol F; Kubes V; Lipina R; Slaby O; Kren L; Sana J
    Cancer Genomics Proteomics; 2022; 19(2):151-162. PubMed ID: 35181585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma.
    Svendsen A; Verhoeff JJ; Immervoll H; Brøgger JC; Kmiecik J; Poli A; Netland IA; Prestegarden L; Planagumà J; Torsvik A; Kjersem AB; Sakariassen PØ; Heggdal JI; Van Furth WR; Bjerkvig R; Lund-Johansen M; Enger PØ; Felsberg J; Brons NH; Tronstad KJ; Waha A; Chekenya M
    Acta Neuropathol; 2011 Oct; 122(4):495-510. PubMed ID: 21863242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
    Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD
    Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
    Della Puppa A; Persano L; Masi G; Rampazzo E; Sinigaglia A; Pistollato F; Denaro L; Barzon L; Palù G; Basso G; Scienza R; d'Avella D
    J Neurooncol; 2012 Jan; 106(1):33-41. PubMed ID: 21725802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
    Lizarte Neto FS; Rodrigues AR; Trevisan FA; de Assis Cirino ML; Matias CCMS; Pereira-da-Silva G; Peria FM; Tirapelli DPDC; Carlotti CG
    Brain Res; 2019 Oct; 1720():146302. PubMed ID: 31226325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAD18 mediates resistance to ionizing radiation in human glioma cells.
    Xie C; Wang H; Cheng H; Li J; Wang Z; Yue W
    Biochem Biophys Res Commun; 2014 Feb; 445(1):263-8. PubMed ID: 24518219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study.
    Wastowski IJ; Simões RT; Yaghi L; Donadi EA; Pancoto JT; Poras I; Lechapt-Zalcman E; Bernaudin M; Valable S; Carlotti CG; Flajollet S; Jensen SS; Ferrone S; Carosella ED; Kristensen BW; Moreau P
    Am J Pathol; 2013 Feb; 182(2):540-52. PubMed ID: 23219427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
    Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
    J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
    Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
    BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
    Oberstadt MC; Bien-Möller S; Weitmann K; Herzog S; Hentschel K; Rimmbach C; Vogelgesang S; Balz E; Fink M; Michael H; Zeden JP; Bruckmüller H; Werk AN; Cascorbi I; Hoffmann W; Rosskopf D; Schroeder HW; Kroemer HK
    BMC Cancer; 2013 Dec; 13():617. PubMed ID: 24380367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
    Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
    Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
    Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
    Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme.
    Zhou H; Miki R; Eeva M; Fike FM; Seligson D; Yang L; Yoshimura A; Teitell MA; Jamieson CA; Cacalano NA
    Clin Cancer Res; 2007 Apr; 13(8):2344-53. PubMed ID: 17438093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.